Labcorp Holdings Inc

Latest Results (17.12.2024):

Revenue Growth

Labcorp Holdings Inc. reported a revenue of $3.28 billion for the third quarter of 2024, marking an increase from $3.06 billion in the same quarter of the previous year. This growth was driven by strong performance in both Diagnostics and Biopharma Laboratories, with robust organic growth contributing significantly to the overall revenue increase.

Earnings Per Share

For the third quarter of 2024, Labcorp Holdings Inc. reported a diluted earnings per share (EPS) of $2.00, compared to $2.11 in the third quarter of 2023. However, the adjusted EPS showed an improvement, rising to $3.50 from $3.38 in the previous year, reflecting the company's focus on core business growth and operational efficiencies.

Free Cash Flow

Labcorp Holdings Inc. generated a free cash flow of $162 million in the third quarter of 2024, slightly down from $171 million in the same period last year. The company continues to focus on strategic investments and acquisitions to support its growth initiatives, which impacted the free cash flow during this quarter.

Updated Full-Year Guidance

Labcorp Holdings Inc. updated its full-year 2024 guidance, projecting a revenue growth range of 6.6% to 7.3%. The adjusted EPS guidance was revised to a range of $14.30 to $14.70, with a slight decrease at the midpoint due to adverse weather impacts. The company also anticipates free cash flow to be between $850 million and $980 million for the year.

Dividend Announcement

Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share of common stock, payable on December 13, 2024, to stockholders of record as of November 26, 2024. This reflects the company's commitment to returning value to shareholders while continuing to invest in growth opportunities.